Development of a multi-institutional prediction model for three-year survival status in patients with uterine leiomyosarcoma (Agog11-022/qcgc1302 study)

Ka Yu Tse*, Richard Wing Cheuk Wong, Angel Chao, Shir Hwa Ueng, Lan Yan Yang, Margaret Cummings, Deborah Smith, Chiung Ru Lai, Hei Yu Lau, Ming Shyen Yen, Annie Nga Yin Cheung, Charlotte Ka Lun Leung, Kit Sheung Chan, Alice Ngot Htain Chan, Wai Hon Li, Carmen Ka Man Choi, Wai Mei Pong, Hoi Fong Hui, Judy Ying Wah Yuk, Hung YaoNancy Wah Fun Yuen, Andreas Obermair, Chyong Huey Lai, Philip Pun Ching Ip*, Hextan Yuen Sheung Ngan

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

3 引文 斯高帕斯(Scopus)

摘要

Background: The existing staging systems of uterine leiomyosarcoma (uLMS) cannot classify the patients into four non-overlapping prognostic groups. This study aimed to develop a prediction model to predict the three-year survival status of uLMS. Methods: In total, 201 patients with uLMS who had been treated between June 1993 and January 2014, were analyzed. Potential prognostic indicators were identified by univariate models followed by multivariate analyses. Prediction models were constructed by binomial regression with 3-year survival status as a binary outcome, and the final model was validated by internal cross-validation. Results: Nine potential parameters, including age, log tumor diameter, log mitotic count, cervical involvement, parametrial involvement, lymph node metastasis, distant metastasis, tumor circumscription and lymphovascular space invasion were identified. 110 patients had complete data to build the prediction models. Age, log tumor diameter, log mitotic count, distant metastasis, and circumscription were significantly correlated with the 3-year survival status. The final model with the lowest Akaike’s Information Criterion (117.56) was chosen and the cross validation estimated prediction accuracy was 0.745. Con-clusion: We developed a prediction model for uLMS based on five readily available clinicopathologic parameters. This might provide a personalized prediction of the 3-year survival status and guide the use of adjuvant therapy, a cancer surveillance program, and future studies.

原文英語
文章編號2378
期刊Cancers
13
發行號10
DOIs
出版狀態已出版 - 02 05 2021

文獻附註

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

指紋

深入研究「Development of a multi-institutional prediction model for three-year survival status in patients with uterine leiomyosarcoma (Agog11-022/qcgc1302 study)」主題。共同形成了獨特的指紋。

引用此